However, DDX3X has garnered significant attention in recent years and is emerging as a potential therapeutic target for cancer therapy due to its frequent mutations and altered expression in a range of malignancies [48, 49], including prostate cancer [19], pancreatic cancer [50], colorectal cancer [13], head and neck squamous cell carcinoma (HNSCC) [51], oral squamous cell carcinoma [52], breast cancer [53], hepatocellular carcinoma [54], lymphomagenesis [20], and lung cancer [22, 23]. This evidence concerns the gene DDX3X and familial pancreatic carcinoma.